The atypical antipsychotics risperidone, clozapine and olanzapine differ regarding their sedative potency in rats

Neuropsychobiology

Volumn 48, Issue 1, 2003, Pages 47-54

  Ahnaou, A ^a,b   Megens, A A H P ^a   Drinkenburg, W H I M ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Antipsychotic; Clozapine; Olanzapine; Quantitative EEG analysis; Rat; Risperidone; Sedation

Indexed keywords

APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENCY; ELECTROENCEPHALOGRAM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CLOZAPINE; CONSCIOUS SEDATION; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ELECTROENCEPHALOGRAPHY; FOURIER ANALYSIS; HYPNOTICS AND SEDATIVES; MALE; PIRENZEPINE; RATS; RATS, WISTAR; RISPERIDONE; STEREOTYPED BEHAVIOR; TIME FACTORS;

EID: 0041672505     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071829     Document Type: Article

References (39)

1. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA: Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661-670.
2. Megens AAHP, Awouters FHL, Schotte A, Meert TF, Dugovic C, Niemegeers CJE, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 1994;114:9-23.
3. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73.
4. Meltzer HY, Matsubara S, Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251:238-246.
5. Bymaser FP, Hemrick-Lueke SK, Pery KW, Fuller RW: Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 1996;124:87-94.
6. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, Moore NA: In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsychotic drug. J Clin Psychiatry 1997;58(suppl 10):28-36.
7. Barnes TR, McPhilllips MA: Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry 1999;174:34-43.
8. Conley RR: Risperidone side effects. J Clin Psychiatry 2000;61:20-25.
9. Conley RR, Meltzer HY: Adverse events related to olanzapine. J Clin Psychiatry 2000;61: 26-29.
10. Miller DD: Review and management of clozapine side effects. J Clin Psychiatry 2000;61:14-17.
11. Dugovic C, Wauquier A, Janssen PAG: Differential effects of the new antipsychotic risperidone on sleep and wakefulness in the rat. Neuropharmacology 1989;28:1431-1433.
12. Ongini E, Bonizzoni E, Ferri N, Milani S, Trampus M: Differential effects of dopamine D-1 and D-2 receptor antagonists on sleep-wake patterns in the rat. J Pharmacol Exper Ther 1993;266:726-731.
13. Spierings EL, Dzoljic MR, Godschalk M: Effect of clozapine on the sleep pattern in the rat. Pharmacology 1977;15:551-556.
14. Dursun SM, Patel JK, Burke JG, Reveley MA: Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: A pilot study. J Psychiatr Neurosci 1999;24:333-337.
15. Touyz SW, Saayman GS, Zabow T: A psychophysiological investigation of the long-term effects of clozapine upon sleep patterns of normal young adults. Psychopharmacology 1978;56: 69-73.
16. Charpley AL, Vassalo CM, Cowen PJ: Olanzapine increases slow wave sleep: Evidence for blockade of central 5 HT(2C) receptors in vivo. Biol Psychiatr 2000;47:468-470.
17. Herrmann WM: EEG-Features of psychophar-ma in clinical-pharmacological experiments; in Saletu B, Krijzer F, Ferber G, Anderer P (eds): Electrophysiological Brain Research in Preclinical and Clinical Pharmacology and Related Fields - An Update. Wien, Facultas Universitätsverlag, 2000, pp 80-103.
18. Kropf W, Kuschinsky K: Electroencephalographic correlates of the sedative effects of dopamine agonists presumably acting on auto-receptors. Neuropharmacology 1991;30:953-960.
19. Sebban C, Tesolin-Decros B, Millan MJ, Spedding M: Contrasting EEG profiles elicited by antipsychotic agents in the prefrontal cortex of the conscious rat: Antagonism of the effects of clozapine by modafinil. Br J Pharmacol 1999; 128:1055-1063.
20. Lee DY, Lee KU, Kwon JS, Jang IJ, Cho MJ, Shin SG, Woo JI: Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers. Psychopharmacology 1999;144:272-280.
21. Hughes AM, Lynch P, Rhodes J, Ervine CM, Yates RA: Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers. Br J Clin Pharmacol 1999;48:323-330.
22. Czobor P, Volavka J: Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients. J Clin Psychopharmacol 1993;13:332-342.
23. Herrmann WM, Fichte K, Itil TM, Kubicki ST: Development of a classification rule for four clinical therapeutic psychotropic drug classes with EEG power spectrum variables of human volunteers. Pharmacopsychiatr Neuropsychopharmacol 1979;12:20-34.
24. Roubieck J, Major I: EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics. Biol Psychiatr 1977;12:613-633.
25. Saletu B, Grunberger J, Linzmayer L, Anderer P: Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry. Pharmacopsychiatry 1987;20:12-27.
26. Malow BA, Reese KB, Sato S, Bogard PJ, Malhotra AK, Su TP, Pickar D: Spectrum of EEG abnormalities during clozapine treatment. Electroencephal Clin Neurophysiol 1994;91: 205-211.
27. Kapur S, Zipursky RB, Remington G: Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatr 1999;156:286-293.
28. Finney DJ: Probit Analysis. Cambridge, Cam-bridge University Press, 1962.
29. Borbély AA, Neuhaus HU: Sleep deprivation: Effects on sleep and EEG in the rat. J Comp Physiol 1979;133:71-87.
30. Dimpfel W, Decker H: Classification of sulpiride, clozapine and haloperidol by toposelective recording from different brain structures in the immobilized rat (stereo-EEG). Neuropsychobiology 1985;14:157-164.
31. Potter WZ: Psychotropic medications and work performance. J Occupational Med 1990; 32:355-361.
32. Andersson JL, Marcus M, Nomikos GG, Svensson TH: Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostrial dopaminergic system. Naunyn Schmiedebergs Arch Pharmacol 1994;349: 236-243.
33. Gallager DW, Aghajanian GK: Effect of antipsychotic drugs on the firing of dorsal raphe cells. 1. Role of adrenergic system. Eur J Pharmacol 1976;39:341-355.
34. Baraban JM, Aghajanian GK: Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 1980;419:355-363.
35. De Mora RS, Rios AAS, De Oliveria LF, Resende ÂC, De Lemos Neto M, Santos EJA, Correia MLG, Tano T: The effects of nitric oxide synthase inhibitors on the sedative effect of clonidine. Anesth Analg 2001;93:1217-1221.
36. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compound. Life Sci 2000;68: 29-39.
37. Ongini E, Longo VG: Dopamine receptor subtyps and arousal. Int Rev Neurobiol 1989;31: 239-255.
38. Trampus M, Ongini E: The D-1 dopamine receptor antagonist SCH 23390 enhances REM sleep in the rat. Neuropharmacology 1990;29: 889-893.
39. Ongini E, Bo P, Dionisitti S, Trampus M, Savoldi F: Effects of remoxipride, a dopamine D-2 antagonist antipsychotic, on sleep-waking patterns and EEG activity in rats and rabbits. Psychopharmacology 1992;107:236-242.